SRR1500868
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.428
- KRAS_SIGNALING_DN+0.382
- HEDGEHOG_SIGNALING+0.204
- SPERMATOGENESIS+0.182
- ESTROGEN_RESPONSE_LATE+0.155
- UV_RESPONSE_DN+0.144
- APICAL_SURFACE+0.133
- BILE_ACID_METABOLISM+0.131
- MYOGENESIS+0.112
- ESTROGEN_RESPONSE_EARLY+0.104
Top 10 suppressed
- MYC_TARGETS_V1-0.624
- INTERFERON_ALPHA_RESPONSE-0.530
- E2F_TARGETS-0.528
- MYC_TARGETS_V2-0.503
- UNFOLDED_PROTEIN_RESPONSE-0.500
- G2M_CHECKPOINT-0.441
- DNA_REPAIR-0.433
- MTORC1_SIGNALING-0.432
- TNFA_SIGNALING_VIA_NFKB-0.430
- PROTEIN_SECRETION-0.424
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1337909 | GTEX | — | 0.969 |
| 2 | SRR1388378 | GTEX | — | 0.969 |
| 3 | SRR1477080 | GTEX | — | 0.966 |
| 4 | SRR1314958 | GTEX | — | 0.959 |
| 5 | SRR1341277 | GTEX | — | 0.959 |
| 6 | SRR1431307 | GTEX | — | 0.957 |
| 7 | SRR1485542 | GTEX | — | 0.957 |
| 8 | SRR1471350 | GTEX | — | 0.956 |
| 9 | SRR1435484 | GTEX | — | 0.955 |
| 10 | SRR1488672 | GTEX | — | 0.951 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.428 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.382 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.204 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.182 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.155 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.144 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.133 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.131 | Inavolisib | — uncovered |
| MYOGENESIS | 0.112 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.104 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.062 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.052 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.011 | Remibrutinib | — uncovered |